Clinical Research Programs

 
News Articles for Clinical Research Programs top ^
2014/3/6
Alkermes plc (NASDAQ: ALKS) today announced the initiation of the pivotal clinical development program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD). The comprehensive pivotal program, named FORWARD ( F ocused O n R esults W ith A R ethinking of D epression), includes a total of 12 studies, including three core phase 3 efficacy studies and nine supportive studies.
Sign-up for Alkermes Announces Initiation of ALKS 5461 Pivotal Clinical Program for Treatment of Major Depressive Disorder investment picks
– Epizyme Also Achieves $4 Million Development Candidate Milestone with GSK – – 2013 End-of-Year Cash Guidance Increased – – Five Clinical Proof of Concept Programs Planned in 2014 – CAMBRIDGE, Mass.
Sign-up for Epizyme and Celgene Advance EPZ-5676 DOT1L Inhibitor Clinical Program to Benefit Cancer Patients with Acute Leukemias, Achieving $25 Million Clinical Proof of Concept Milestone investment picks
2013/12/19
Collaboration represents the first time the ACC's PINNACLE Registry Research Alliance will be used for clinical trial recruitment PARIS and TARRYTOWN, N.Y. , Dec.
Sign-up for Sanofi and Regeneron Announce Collaboration with American College of Cardiology for PCSK9 Inhibitor Clinical Program investment picks
Incyte Corporation (Nasdaq: INCY) today reported second-quarter 2013 financial results, including revenue from Jakafi ® (ruxolitinib), which is approved by the U.S. Food & Drug Administration (FDA) for the treatment of patients with intermediate or high-risk myelofibrosis (MF). The Company also increased its 2013 net product revenue guidance to a range of $220 million to $230 million, a change from the previous range of $210 million to $225 million; highlighted additional positive data recently presented at key scientific meetings for its lead JAK1 and JAK2 inhibitors, Jakafi and baricitinib, and its novel immunotherapy, INCB24360, an oral IDO1 inhibitor; and described progress for several other clinical programs, including additional potential indications for Jakafi.
Sign-up for Incyte Reports Second-Quarter 2013 Financial Results; Increases Revenue Guidance; Updates Shareholders on Key Clinical Programs investment picks
2014/4/1
-- Conference Focuses on New Drug Development and Cutting Edge Research in Schizophrenia --
Sign-up for Omeros Invited to Present on OMS824 Phase 2 Clinical Program at the Schizophrenia International Research Conference investment picks
2013/10/31
Incyte Corporation (Nasdaq: INCY) today reported third-quarter 2013 financial results, including revenue from Jakafi ® (ruxolitinib), which is approved by the U.S. Food & Drug Administration (FDA) for the treatment of patients with intermediate or high-risk myelofibrosis (MF). The Company also described: positive top-line results of its Phase II trial (RECAP) of ruxolitinib in patients with refractory metastatic pancreatic cancer; positive Phase II proof-of-concept data recently presented at key scientific meetings for its lead JAK1 inhibitor, INCB39110; and progress for several of its other key clinical programs.
Sign-up for Incyte Reports Third-Quarter 2013 Financial Results; Updates Shareholders on Key Clinical Programs investment picks
2013/11/14
http://media.marketwire.com/attachments/201303/136696_CurrentHeathLogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1068590&ProfileId=051205&sourceType=1 CHAPEL HILL, NC --
Sign-up for Heat Biologics, Inc. Reports Third Quarter 2013 Financial Results and Provides Clinical Programs Review investment picks
2014/2/12
Incyte Corporation (Nasdaq: INCY) today reported 2013 fourth-quarter and year-end financial results, including revenue from Jakafi ® (ruxolitinib), which is approved by the U.S. Food & Drug Administration (FDA) for the treatment of patients with intermediate or high-risk myelofibrosis (MF). The Company also provided 2014 financial guidance and highlighted multiple achievements in its clinical programs, including agreement with the FDA for a Special Protocol Assessment (SPA) for a registration trial of ruxolitinib in patients with advanced or metastatic pancreatic cancer.
Sign-up for Incyte Reports 2013 Fourth-Quarter and Year-End Financial Results; Provides 2014 Financial Guidance; Updates Shareholders on Key Clinical Programs investment picks
2013/11/4
Company Instructed to Request Lifting of Full Clinical Hold for Oral Proellex for the Treatment of Uterine Fibroids Oral Study to be Conducted in Parallel to Vaginal Phase 2b Study THE WOODLANDS, Texas, Nov.
Sign-up for Repros Receives FDA Guidance for Proellex(R) Low Dose Oral Uterine Fibroid Clinical Program investment picks
2014/3/4
-- Successful Phase 1 Results Set the Stage for Trials in Patients with Life-Threatening Blood Disorders --
Sign-up for Omeros Submits IND to Advance OMS721 Phase 2 Clinical Program investment picks
WALTHAM, Mass., Sept.
Sign-up for TESARO Announces Initiation of Rolapitant IV Clinical Program investment picks
-Sativex Already Undergoing Phase 3 Program in the U.S. as a Treatment for Cancer Pain- LONDON , Aug.
Sign-up for GW Pharmaceuticals plc Opens an Investigational New Drug Application (IND) in the United States for a Sativex® Phase 3 Clinical Program as a Treatment for Spasticity Due to Multiple Sclerosis investment picks
2013/11/12
-- OMS302 also to be Featured in "Cutting Edge" Symposium --
Sign-up for Omeros to Present Data from OMS302 Phase 3 Clinical Program at the American Academy of Ophthalmology Annual Meeting investment picks
FDA instructs Repros to request meeting to discuss adequacy of studies ZA-301 and ZA-302 as evidence of pivotal efficacy FDA will now consider label claims versus approved testosterone products if superiority can be demonstrated FDA confirms current safety package acceptable pending final outcomes FDA now requires 1 year exposure for men up-titrated to high dose in DEXA study Company now guides to a 2 nd half 2014 NDA submission FDA will consider priority review at time of NDA submission THE WOODLANDS, Texas, Oct.
Sign-up for Repros Receives FDA Guidance For Androxal(R) Clinical Program investment picks
2013/11/4
MORRIS PLAINS, N.J., Nov.
Sign-up for Immunomedics Announces First Quarter Fiscal 2014 Results and Clinical Program Developments investment picks
2014/1/13
http://media.marketwire.com/attachments/200711/383726_AliosBioPharmalogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1081077&ProfileId=051205&sourceType=1 SOUTH SAN FRANCISCO, CA --
Sign-up for Alios BioPharma Reports Significant Progress With Its Clinical Program for AL-8176, Its Nucleoside Analog for the Treatment of Respiratory Syncytial Virus (RSV) investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Clinical Research Programs
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Clinical Research Activities  |  Next: Clinical Research Study